INOpulse Promising for Pulmonary Hypertension With Pulmonary Fibrosis
Positive topline data from the phase 2b study of INOpulse® delivery system announced for the treatment of pulmonary hypertension associated with pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
Thrombomodulin Alfa Not Recommended for Idiopathic Pulmonary Fibrosis
Use of thrombomodulin alfa for the treatment of acute exacerbation of idiopathic pulmonary fibrosis is not recommended, according to phase 3 clinical trial results.
Idiopathic Pulmonary Fibrosis Annualized Costs Totals More Than $10,000 Per Patient
Patients with idiopathic pulmonary fibrosis are faced with a heavy economic burden, with mean annual costs for admission and inpatient care totaling more than $10,000 per patient.
Idiopathic Pulmonary Fibrosis Susceptibility Identified Via Genomic Markers
Altered expression of 14 genes in adults was associated with idiopathic pulmonary fibrosis susceptibility.
Chronic Viral Infection May Increase Idiopathic Pulmonary Fibrosis Risk
Persistent or chronic, but not acute, viral infections significantly increase the risk of developing idiopathic pulmonary fibrosis.
Home Oxygen Use Associated With Worsened Physical Function in COPD and IPF
Use of home oxygen is associated with reduced physical function in patients with either COPD or idiopathic pulmonary fibrosis.
Sarcoidosis on Associated With Higher Mortality vs COPD, IPF on Transplant List
Patients with sarcoidosis on the lung transplant waiting list had a higher mortality rate than patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis.
Plasma Biomarkers of Idiopathic Pulmonary Fibrosis May Predict Survival
Plasma biomarkers of progressive idiopathic pulmonary fibrosis may be markers of progressive pulmonary fibrosis regardless of the type of interstitial lung disease.
Short-Term Effectiveness of Antifibrotics in Idiopathic Pulmonary Fibrosis
Patients taking the antifibrotic medications nintedanib and pirfenidone for idiopathic pulmonary fibrosis had reduced all-cause mortality and hospitalizations for up to 2 years compared with a matched untreated cohort.
Nintedanib Discontinuation in Idiopathic Pulmonary Fibrosis Related to Anorexia
In patients with idiopathic pulmonary fibrosis, anorexia and weight loss during prior treatment with pirfenidone was associated with early termination of subsequent nintedanib therapy.
Next post in Restrictive Lung Disease
